18F/68Ga-SMIC-4200 PET/CT quantification of HER2 expression in locally advanced or metastatic urothelial carcinoma to guide HER2-targeted drug therapy

开始日期2024-09-01

申办/合作机构

上海市第十人民医院

NCT06488807 / RecruitingN/AIIT

Treatment of Perioperative Neurocognitive Disorders With Olfactory Enrichment: Study Protocol for a Randomized Controlled Trial

Perioperative neurocognitive disorder (PND) is one of the most common postoperative complications among elderly patients. However, the mechanism and targeted intervention of PND remains unclear. Our previous clinical studies demonstrated the association between olfactory impairment and PND. Moreover, our translational studies showed that anesthesia/surgery induced olfactory impairment and caused cognitive impairment in mice and olfactory enrichment could prevent the anesthesia/surgery-induced cognitive impairment. However, there was no clinical investigation to determine whether olfactory enrichment can mitigate PND in elderly patients. Therefore, we propose determining whether olfactory enrichment can prevent and/or treat PND in elderly patients.

开始日期2024-08-01

申办/合作机构

上海市第十人民医院

[+1]

NCT06418685 / Not yet recruitingN/AIIT

The First Affiliated Hospital of Naval Medical University

This study is a multi-center prospective cohort study, which plans to include 300 patients with chronic functional constipation to treat with Vibrabot capsules, and at the same time, include ≥300 patients receiving constipation treatment during the same period.
During the study, it is necessary to collect the patients' basic information, baseline constipation status and treatment information, capsule intake during treatment, and concomitant medication. During the treatment phase, patients follow the doctor's advice to receive Vibrabot capsule treatment and maintain stable dietary intake and exercise according to the constipation diagnosis and treatment guidelines.
During the study, patients need to scan the two-dimensional code or search for the electronic questionnaire "Vibrabot Health" Official Account on WeChat, and fill in the relevant information during the treatment in the electronic questionnaire in a timely and truthful manner. The treatment effect of the patients is evaluated by assessing the number of occurrences of spontaneous bowel movements (SBM) and complete spontaneous bowel movements (CSBM).

开始日期2024-06-01

申办/合作机构

上海市第十人民医院

[+4]

100 项与上海市第十人民医院相关的临床结果

登录后查看更多信息

0 项与上海市第十人民医院相关的专利（医药）

登录后查看更多信息

726

项与上海市第十人民医院相关的文献（医药）

2024-08-01·Biochemical genetics

FTO Knockdown-Mediated Maturation of miR-383-5p Inhibits Malignant Advancement of Pancreatic Cancer by Targeting ITGA3

Article

作者: Han, Shilong ; Zhang, Wei ; Ding, Anle ; Li, Maoquan ; Xu, Minjie ; Yuan, Yifeng

m6A demethylase FTO is confirmed to be involved in pancreatic cancer progression. FTO regulates miRNA processing. To investigate the regulatory effect of FTO on miR-383-5p and its role in pancreatic cancer. The expression of miR-383-5p, ITGA3, and FTO was predicted using bioinformatic analysis in tissues and was measured using qPCR in cells. Cell biological functions were investigated using MTT assay, Transwell assay, sphere formation assay, and qPCR. The targeting relationship between miR-383-5p and ITGA3 was evaluated using the dual-luciferase reporter assay. The effect of FTO on miR-383-5p processing was evaluated using RIP and MeRIP assay. FTO expression was upregulated in pancreatic cancer and silencing of FTO promoted the processing of miR-383-5p in an m6A-dependent manner. m6A-modified miRNA processing was recognized by IGF2BP1. Downregulation of miR-383-5p reversed FTO knockdown-induced inhibition of cellular processes. The FTO/miR-383-5p/ITGA3 axis facilitated cell viability, metastasis, and stemness in pancreatic cancer.

2024-07-01·Journal of the European Academy of Dermatology and Venereology : JEADV

Expert consensus on perioperative integrated skincare for noninvasive energy‐based device aesthetic procedures in clinical practice in China

Article

作者: Zhang, Wei ; Xu, Xiaoke ; He, Wei ; Zhao, Xiaozhong ; Zheng, Zhizhong ; Chen, Xiangdong ; Li, Kai ; Lin, Tong ; Gao, Lin ; Liu, Zhenfeng ; Wu, Yan ; Liu, Wei ; Yu, Bo ; Xiang, Leihong ; Song, Weimin ; Xie, Hongfu ; Zhou, Zhanchao ; Gu, Jun ; Qin, Xiaolei ; Yang, Bin ; Zou, Ying ; Li, Xueli ; Wang, Weizhen ; Liu, Hongmei ; Fan, Weixin ; Li, Hengjin ; Hao, Fei ; Ju, Qiang ; Yan, Yan ; Li, Shanshan ; Wang, Baoxi ; Yuan, Chao ; Ren, Jie ; Liang, Hong ; Zhang, Chengfeng ; Wu, Wenyu

Abstract:

Background:

Noninvasive energy‐based device (NI‐EBD) aesthetic procedures has recently gained widespread usage for treating various skin conditions, enhancing skin texture and performing rejuvenation‐related procedures. However, practically all NI‐EBD procedures result in variable degrees of damage to the skin barrier, inducing pathological and physiological processes such as oxidative stress and inflammation, and only a small percentage of individuals possess the innate ability to restore it.

Objective:

To introduce the concept of integrated skincare and establish standardized operational procedures for perioperative integrated skincare, and furnish a theoretical basis for clinical diagnosis and treatment performed by professional medical aestheticians.

Methods:

The author leveraged domestic and international guidelines, clinical practice expertise and evidence‐based research, adapting them to suit the specific circumstances in China.

Results:

The consensus were provided four parts, including concept and essence of integrated skincare, integrated skincare significance during the perioperative phase of NI‐EBD procedures, active ingredients and functions of effective skincare products, standardized perioperative skincare procedure for NI‐EBD procedures and precautions. For the standardized perioperative skincare procedure, four recommendations were listed according to different stages during NI‐EBD procedures.

Conclusion:

These recommendations create the ‘Expert Consensus on Perioperative Integrated Skincare for Noninvasive Energy‐Based Device Aesthetic Procedures in Clinical Practice in China’.

2024-06-01·Biochimica et biophysica acta. Molecular basis of disease

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy

Article

作者: Liu, Yu ; Miao, Yuqing ; Xu, Qing ; Zhang, Dan ; Xu, Dongge ; Yang, Yang ; He, Susu ; Li, Erguang ; Cheng, Yan

Lymphotoxin α (LTα) is a soluble factor produced by activated lymphocytes which is cytotoxic to tumor cells. Although a promising candidate in cancer therapy, the application of recombinant LTα has been limited by its instability and toxicity by systemic administration. Secreted LTα interacts with several distinct receptors for its biological activities. Here, we report a TNFR1-selective human LTα mutant (LTα Q107E) with potent antitumor activity. Recombinant LTα Q107E with N-terminal 23 and 27 aa deletion (named LTα Q1 and Q2, respectively) showed selectivity to TNFR1 in both binding and NF-κB pathway activation assays. To test the therapeutic potential, we constructed an oncolytic adenovirus (oAd) harboring LTα Q107E Q2 mutant (named oAdQ2) and assessed the antitumor effect in mouse xenograft models. Intratumoral delivery of oAdQ2 inhibited tumor growth. In addition, oAdQ2 treatment enhanced T cell and IFNγ-positive CD8 T lymphocyte infiltration in a human PBMC reconstituted-SCID mouse xenograft model. This study provides evidence that reengineering of bioactive cytokines with tissue or cell specific properties may potentiate their therapeutic potential of cytokines with multiple receptors.

项与上海市第十人民医院相关的新闻（医药）

2024-09-30

·荣昌生物

2024 CSCO｜在“最好的时代”，爱地希®引领尿路上皮癌精准诊疗，全面超越

中国原创爱地希®（维迪西妥单抗）是全球唯一获批上市、精准靶向HER2治疗晚期尿路上皮癌的抗体药物偶联物（ADC）。自2021年上市以来，维迪西妥单抗一直是全球尿路上皮癌（包括：膀胱癌、UTUC）精准治疗的布道者。2024年，含维迪西妥单抗的C014、C017、DV-G001研究相继在ASCO、ESMO和CSCO报道，其在短期ORR、pCR和长期OS数据方面，遥遥领先全球。维迪西妥单抗用精准诊疗和卓越疗效，定义HER2表达尿路上皮癌诊疗全球风向标，近20项原创研究已“刷爆”美国临床肿瘤学年会（ASCO）、欧洲肿瘤内科学会（ESMO）两场具有全球影响力的学术会议。9月ESMO大会上，维迪西妥单抗荣昌生物开展的中国C014（中国人群）研究与国际合作伙伴辉瑞开展的DV-G001（欧美人群）研究在晚期尿路上皮癌同时获得同样数值的ORR 75%，完美超越EV302维恩妥尤单抗 ORR66.7%，这也是目前国际最高的有效率数据。DV-G001研究更在肿瘤完全缓解率CR甩出了一张“王牌”，高达惊人的35%。在长期生存方面，一二线混合的C014研究（一线60%，二线及后线40%）中位OS达到33.1月，继续完美超越EV302维恩妥尤单抗中位OS 31.5月。 9月28日上午，由CSCO尿路上皮癌专家委员会主办、荣昌生物独家支持的“2024 CSCO尿路上皮癌专场”火热开讲。北京大学第一医院何志嵩教授、北京大学肿瘤医院郭军教授、上海复旦肿瘤医院叶定伟教授、四川大学华西医院魏强教授、大连医科大学附属第一医院刘基威教授、天津市肿瘤医院姚欣教授、中山大学肿瘤中心/中山大学肿瘤医院刘卓炜教授、北京大学第一医院虞巍教授、北京大学第一医院张崔建教授、中国医学科学院肿瘤医院寿建忠教授、上海市第十人民医院姚旭东教授、北京大学肿瘤医院盛锡楠教授、中国医学科学院肿瘤医院山西医院瓦斯里江·瓦哈甫教授、中国医学科学院周爱萍教授携手众多中国权威专家，探讨尿路上皮癌领域最新研究与发展趋势，再次展示了维迪西妥单抗联合疗法在HER2表达尿路上皮癌的晚期治疗、新辅助及围手术期治疗和保膀胱治疗中的多项数据。会议伊始，大会主席何志嵩教授、郭军教授分别致开幕词。何志嵩教授回顾了专委会自2019年以来成立的发展历程，希望通过学术的交流碰撞推动尿路上皮癌精准治疗不断发展。郭军教授表示，ADC、免疫等新型疗法的横空出世，使尿路上皮癌治疗发生了翻天地覆的变革。 ▲自左至右：中国医学科学院肿瘤医院寿建忠教授、大连医科大学附属第一医院刘基威教授、四川大学华西医院魏强教授、北京大学第一医院何志嵩教授、北京大学肿瘤医院郭军教授、天津市肿瘤医院姚欣教授、中山大学肿瘤中心/中山大学肿瘤医院刘卓炜教授、上海市第十人民医院姚旭东教授随后，与会专家为《CSCO尿路上皮癌诊疗指南(2024版)》揭幕。正式发布的新版《指南》将为临床肿瘤医生提供助力，为尿路上皮癌患者带来更好的诊疗。据了解，维迪西妥单抗凭借卓越的疗效和安全性获得了指南推荐，并明确推荐对所有局部晚期或转移性尿路上皮癌患者实施HER2免疫组化检测。接下来进入气氛热烈的学术交流环节。北京大学第一医院张崔建教授讲解了维迪西妥单抗联合特瑞普利单抗用于肌层浸润性尿路上皮癌的新辅助II期临床研究的情况。初步结果显示病理完全缓解（pCR）率为61.3%，病理部分缓解率（pPR）达74.2%，远超以往免疫联合化疗或单一治疗的疗效。这一发现标志着ADC联合PD-1可能会彻底改变尿路上皮癌的治疗策略，成为MIBC新辅助治疗的新趋势。中国医学科学院肿瘤医院山西医院的瓦斯里江·瓦哈甫教授，分析了维迪西妥单抗+替雷利珠单抗新辅助治疗HER2过表达局部晚期肌层浸润性膀胱癌的HOPE-03研究，16例可评估的患者中，cCR为68.75%，DCR为90.91%；14例患者选择放疗行保膀胱治疗，6例患者放疗后肿瘤消失；2例患者接受膀胱根治手术。瓦斯里江教授表示，“维迪西妥单抗+替雷利珠单抗”作为一种新型新辅助治疗方案，展现了卓越降期效果和可控的安全性。北京大学第一医院虞巍教授表示，华西医院回顾性发现，中国尿路上皮癌患者的HER2 IHC表达率约占80%。HER2表达患者使用抗HER2 ADC药物可有效改善临床结局。无论HER2 IHC过表达或低表达的患者，维迪西妥单抗单药或联合免疫治疗带来的ORR疗效优于化疗和免疫单药治疗。北京大学肿瘤医院盛锡楠教授作《晚期尿路上皮癌治疗进展及研究述评》报告，指出尿路上皮癌经历了化疗到精准治疗的时代，特别是ADC药物成为国内外的“爆款”，而HER2 ADC维迪西妥单抗展现了显著的优势，并成为该领域的重要选择。作为目前全球唯一获批的靶向HER2的ADC药物，维迪西妥单抗在局部晚期或转移性尿路上皮癌的患者中显示出明显疗效。HER2表达检测可协助筛选靶向治疗潜在获益人群，还可以为晚期患者提供可能的治疗方案。与会专家就“精准治疗时代下ADC的治疗决策与靶点分子检测”展开了深入讨论。专家们一致认同，在选择ADC类药物进行临床治疗时，需综合考量包括靶点表达水平、疗效以及安全性在内的多方面因素，期待能够进一步拓宽现有的治疗选项，从而为患者提供更加个性化且高效的治疗解决方案。各位专家对于国内开展的维迪西妥单抗联合特瑞普利单抗对比铂类化疗用于晚期尿路上皮癌一线治疗的随机对照Ⅲ期临床研究（C016）充满期待。该研究已经完成全部入组。“非常期待明年看到研究结果，相信必将为HER2治疗带来革命性的改变，重塑晚期尿路上皮癌一线治疗格局。” 引领精准，使命必达。维迪西妥单抗作为最早在世界尿路上皮癌领域发出“最强音”的中国原创ADC药物，从单药走向联合，从后线走向前线，每一步都展现出惊艳的疗效，引领着精准治疗的方向。随着更多研究数据的出炉，相信维迪西妥单抗将为尿路上皮癌的治疗带来更多里程碑式的变革。文稿 | 危颖影像 | 连鹏编辑 | 春媛荣昌生物科创板上市 | 港交所上市挺进医保 | License out 维迪西妥单抗 | 泰它西普 RC28 | RC108 | RC118

抗体药物偶联物CSCO会议ASCO会议上市批准临床结果

2024-09-08

·美通社

"十"话实说，"心"路同行----波士顿科学助力社区心血管疾病科普

上海 2024年9月8日 /美通社/ -- 9月4日，由东方网东方社区数字苑、静安区彭浦镇、人民阅读、上海市第十人民医院心内科共同开展，波士顿科学支持的"‘十'话实说，‘心'路同行——社区科普活动"，在上海市静安区彭浦镇党群服务中心成功举办。来自上海市第十人民医院心内科的专家团队走进社区，近距离传递心血管健康知识，并与到场居民进行面对面交流，帮助人们提高对疾病危害的认知，引导大家遵循健康的生活方式。医生团队向居民讲解冠心病和房颤健康知识本次科普讲座上，专家就冠心病、心房颤动等常见心脏疾病的诱因、典型症状、临床案例等方面，展开分享，并提出了实用的预防与治疗建议。上海市第十人民医院心内科主任医师车文良教授表示："目前，由于人们生活节奏的加快和饮食结构的转变，高血压、高血脂、高血糖等老年常见慢病愈发常见，在无形中造成了更多、更复杂的心血管疾病风险。因此，作为自身健康的第一责任人，每个人都有必要掌握一些心脏健康知识，防患于未然。" 活动现场吸引了来自静安区彭浦镇周边社区的40余位居民参加，丰富的科普内容还在人民阅读官方微博、视频号线上平台，和东方社区数字苑同步直播，全网观看量达7000多人次，进一步扩大了科普辐射范围，让更广泛的大众受益于医学知识的普及。居民积极互动、跟练康复操 2023年，国家卫生健康委等部门联合发布的《健康中国行动——心脑血管疾病防治行动实施方案（2023—2030年）》明确指出，未来要进一步"加大全民健康教育力度，不断提高健康素养"。未来，波士顿科学也将继续以大众健康为导向，秉承"为生命创新"的承诺，持续赋能健康知识传播，并以丰富的医疗创新优势，为中国人民的长久健康保驾护航。

2024-09-06

·同写意

国内首仿! 派金生物注射用重组替度鲁肽完成Ⅲ期临床首例受试者给药 | 会员动态

临床3期生物类似药

100 项与上海市第十人民医院相关的药物交易

登录后查看更多信息

100 项与上海市第十人民医院相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Autologous adipose stem cell therapy(Shanghai No. 10 People's Hospital)	糖尿病足更多	临床1期
Ad-RGD-Survivin-ZD55-miR-143 ( miR-143 )	结直肠癌更多	临床前
CN118146300 ( HNRNPA1 )专利挖掘	肿瘤更多	药物发现
ZD55-lipocalin-2 ( LCN2 )	胰腺癌更多	无进展